Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection
Harmony L. Tyner, Jefferey L. Burgess, Lauren Grant, Manjusha Gaglani, Jennifer L. Kuntz, Allison L. Naleway, Natalie J. Thornburg, Alberto J. Caban-Martinez, Sarang K. Yoon, Meghan K. Herring, Shawn C. Beitel, Lenee Blanton, Janko Nikolich-Zugich, Matthew S. Thiese, Jessica Flores Pleasants, Ashley L. Fowlkes, Karen Lutrick, Kayan Dunnigan, Young M. Yoo, Spencer RoseHolly Groom, Jennifer Meece, Meredith G. Wesley, Natasha Schaefer-Solle, Paola Louzado-Feliciano, Laura J. Edwards, Lauren E.W. Olsho, Mark G. Thompson
Dive into the research topics of 'Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection'. Together they form a unique fingerprint.